Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

doi:10.3324/haematol.2018.192328

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Haematologica - 1 Sept 2018

Barr Paul M, Robak Tadeusz, Owen Carolyn, Tedeschi Alessandra, Bairey Osnat, Bartlett Nancy L, Burger Jan A, Hillmen Peter, Coutre Steven, Devereux Stephen, Grosicki Sebastian, McCarthy Helen, Li Jianyong, Simpson David, Offner Fritz, Moreno Carol, Zhou Cathy, Styles Lori, James Danelle, Kipps Thomas J, Ghia Paolo

Abstract excerpt

Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic leukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. A total of 269 patients aged ≥65 years with previously untreated chronic lymphocytic leukemia without del(17p) were randomized 1:1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Share to Piperidines

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 29880603
DOI: 10.3324/haematol.2018.192328
PMCID: PMC6119145

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.PMID 29880603Read ↗

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studySemantic proximity Read ↗

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.Semantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.Semantic proximity Read ↗

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.Semantic proximity Read ↗

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read ↗

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.Semantic proximity Read ↗

Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 StudySemantic proximity Read ↗

Chronic lymphocytic leukemia treatment algorithm 2022.Semantic proximity Read ↗

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.Semantic proximity Read ↗

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Semantic proximity Read ↗

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.